Bruker Corporation (BRKR) Lifted to “Neutral” at Bank of America Corporation

Bruker Corporation (NASDAQ:BRKR) was upgraded by investment analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating in a research note issued to investors on Friday.

Other research analysts have also recently issued reports about the company. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Thursday, July 6th. BidaskClub upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Barclays PLC reiterated an “equal weight” rating and set a $30.00 target price (up from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Cowen and Company reiterated a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a report on Friday, July 14th. Finally, J P Morgan Chase & Co upgraded shares of Bruker Corporation from an “underweight” rating to a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $26.70.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The firm had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. During the same period last year, the firm earned $0.32 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/11/03/bruker-corporation-brkr-lifted-to-neutral-at-bank-of-america-corporation.html.

In other news, CEO Frank H. Laukien purchased 2,335 shares of Bruker Corporation stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average price of $27.39 per share, with a total value of $63,955.65. Following the completion of the transaction, the chief executive officer now directly owns 37,791,386 shares of the company’s stock, valued at $1,035,106,062.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Asset Management Americas Inc. lifted its stake in shares of Bruker Corporation by 18.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 73,058 shares of the medical research company’s stock valued at $1,704,000 after buying an additional 11,324 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Bruker Corporation by 20.5% during the 1st quarter. Teachers Advisors LLC now owns 148,229 shares of the medical research company’s stock valued at $3,458,000 after buying an additional 25,225 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Bruker Corporation by 189.8% during the 1st quarter. Legal & General Group Plc now owns 34,905 shares of the medical research company’s stock valued at $815,000 after buying an additional 22,861 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Bruker Corporation by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock valued at $229,391,000 after buying an additional 277,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Bruker Corporation by 7.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 944,553 shares of the medical research company’s stock valued at $22,034,000 after buying an additional 66,344 shares in the last quarter. 65.74% of the stock is owned by institutional investors.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

What are top analysts saying about Bruker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bruker Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit